

# PRESTIGE 24i GENTAMICIN

# DIAGNOSTIC KIT FOR DETERMINATION OF GENTAMICIN CONCETRATION

## INTRODUCTION

Gentamicin is an aminoglycoside antibiotic, used to treat many types of bacterial infections. It works by interrupting bacterial protein synthesis. Gentamicin is not absorbed from the alimentary tract and metabolized in the liver. It is eliminated unchanged in the urine (80-90%). Monitoring gentamicin concentration in serum is recommended because of the a narrow therapeutic range, oto- and nephrotoxic side effects occurring with prolonged (more than 7 days) treatment with high doses of gentamicin and also because of large intersubject variability in pharmacokinetic parameters.

## METHOD PRINCIPLE

Immunoturbidimetric method; inhibition of agglutination.

Increase of absorbance measured at  $\lambda = 700$  nm is inversely proportional to the concentration of gentamic in the sample.

Gentamicin which is present in the sample forms immune complexes with specific antibody contained in the first reagent. After adding a second reagent containing polistyrene latex particles coated with gentamicin, agglutination is inhibited in proportion to gentamicin concentration in the sample.

# REAGENTS

# Package

	Cat. No 4-252	Cat. No 4-382	
	(24-TRAY)	(36-TRAY)	
1-Reagent	2 x 15 ml	2 x 14 ml	
2-Reagent	2 x 6 ml	2 x 5.5 ml	

Unopened reagents stored at 2-8°C are stable up to the expiry date printed on the package. After opening the reagents are stable for 21 days on board the analyser at 2-10°C. Protect from light!

# Reagents composition

Bis-Tris buffer, monoclonal antibodies to gentamicin, polistyrene latex particles coated with gentamicin, sodium azide (< 0.1%).

# Warnings and notes

- Products for in vitro diagnostic use only.
- The reagents should be used by suitably qualified laboratory personnel only in accordance with intended purpose.
- The reagents contain sodium azide as a preservative (< 0.1%). Avoid contact with skin and mucous membranes. Sodium azide can form high explosive metal azide combinations with lead and cooper. Drains should be flushed well with a large amount of water when discarding the solution.
- Mix well Reagent 2 before first use. Avoid foam formation.
- For optimal reagents stability it is recommended to remove them from the system and store in tightly closed bottles at 2-8°C.

# **SPECIMEN**

Serum. Samples may be stored up to 3 days at 2-8 °C. or longer at -20°C. Nevertheless it is recommended to perform the assay with freshly collected samples!

Avoid repeated freezing and thawing. Mix well the samples before analysis.

# **PROCEDURE**

These reagents may be used in automatic analysers Prestige 24i, Biolis 24i and Sapphire 400.



- 1-Reagent and 2-Reagent are ready to use.
- 1-Reagent put on basic position in reagent tray.
- 2-Reagent put on start position in reagent tray.

For reagent blank 0.9% NaCl is recommended.

# APPLICATION

Item name

Data information	
Units	μg/ml

**GENT** 

# Decimals Analysis

1 x 11 ct 1 y 51 5	
Type	END
Main W.Length1	700
Sub W.Length2	
Method	Immunoturbidymetric

## Corr

	Slope		Inter
Y=	1.000	X+	0.000

# Calibration

Type	Linear
Factor	

## Standard

#1	*	#4	*
#2	*	#5	*
#3	*	#6	*

Normal Range

	Male		Female	
	Low	High	Low	High
Serum				
Urine				
Plasma				
CSF				
Dialysis				
Other				

Aspiration

115piration		
Kind	Double	
		1
	Volume	
Sample	3	
Reagent1	230	μl
Reagent2	70	

Third Mix.	OFF
R1 Blank	Water-B

# Monitor

Ī	0 Level Point	1
ĺ	Span	3.000

# **Data Process**

Read			Absorbanc	e Limit	
	Start	End			
Main	53	54		Low	0.000
Sub	34	35		High	3.000

Factor		Endpoint Limit	2.000
Blank correction:	1.0000	Linear Check (%)	90%

#### Dilution

Dilution	
Diluent	100 : Dil2
·	

## **Prozone Check**

	Start	End	Limit (%)	
First				
Second				Low
Third				Low

## **Auto Rerun SW**

	0.7.7		
- 1	ON		
- 1	ION		

Auto Rerun Range (Result)

	OFF	OFF
	Lower	Higher
Serum		
Urine		
Plasma		
CSF		
Dialysis		
Other		

## **Auto Rerun Condition (Absorbance)**

Absorbance Range		
	Lower	OFF
	Higher	OFF
Prozone Range		OFF

## THERAPEUTIC RANGE

Therapeutic concentration:

Therapeutic concentration.			
Cmax*:	severe infections less severe infections	8-10 μg/ml (16.7-20.9 μmol/l) 5-8 μg/ml (10.4-16.7 μmol/l)	
Cmin*:	severe infections moderate infections less severe infections	< 2-4 μg/ml (< 4,2-8,4 μmol/l) < 2 μg/ml (< 4,2 μmol/l) < 1 μg/ml (< 2,1 μmol/l)	

<sup>\*</sup> maximum and minimum drug concentration in blood

Some patients achieve the desired therapeutic response at levels outside this range, so it is recommended to consider the need to establish an individual therapeutic ranges for each patient.

# **QUALITY CONTROL**

For internal quality control it is recommended to use the CORMAY TDM CONTROLS (Cat. No 5-107) with each batch of samples. For the calibration of automatic analysers systems the CORMAY GENTAMICIN CALIBRATORS (Cat. No 5-110) is recommended. The calibration curve should be prepared every 7 days, with change of reagent lot number or as required e.g. quality control findings outside the specified range.

# PERFORMANCE CHARACTERISTICS

Metrological characteristics may differ from values presented below with the instrument used.

- **Sensitivity / Limit of Detection:** 0.07 μg/ml (0.15 μmol/l).
- **Linearity:** up to 10  $\mu$ g/ml (20.9  $\mu$ mol/l). If the gentamicin concentration exceeds 10  $\mu$ g/ml, dilute the sample 1:8 with saline solution and repeat the assay. The dilution take into account when making the results.

# Specificity / Interferences

Haemoglobin up to 0.5 g/dl, bilirubin up to 20 mg/dl, fatty acids up to 3 g/dl, do not interfere with the test.

# Precision

Repeatability (run to run)	Mean	SD	CV
n = 10	[µg/ml]	[µg/ml]	[%]
level 1	3.06	0.037	1.21
level 2	6.09	0.121	1.98
level 3	7.69	0.269	3.50

Reproducibility (day to day)	Mean	SD	CV
n = 10	[µg/ml]	[µg/ml]	[%]
level 1	3.05	0.070	2.28
level 2	6.11	0.126	2.06
level 3	7.87	0.290	3.69

## Method comparison

A comparison between CORMAY reagent (y) and commercially available assay (x) using 50 samples gave following results:

 $y = 0.9284x + 0.0365 \mu g/ml;$ 

R = 0.9931 (R – correlation coefficient)

## WASTE MANAGEMENT

Please refer to local legal requirements.

## LITERATURE

- Oellerich, M. Therapeutic drug monitoring. In: Thomas L, ed. Clinical Laboratory Diagnostics. Use and Assessment of Clinical Laboratory Results. 1st Edition. TH-Books, Frankfurt/Main, Germany, 1998.
- Biosafety in Microbiological and Biomedical Laboratories, Richmond JY, McKinney RW, eds. US Department of Health and Human Services, 4th Edition, 1999.
- Westgard JO, Barry PL. Cost-Effective Quality Control: Managing the Quality and Productivity of Analytical Processes, AACC Press, 1986.
- Young DS. Effects of Drugs on Clinical Laboratory Tests. 5th Edition, AACC Press, 2000.
- Tietz NW. Clinical Guide to Laboratory Tests. WB Saunders Company, Philadelphia, 1990.
- 6. Alan H. B. Wu, Tietz Clinical Guide to Laboratory Tests, W.B. Saunders Company, 4th edition, 1456 (2006).

Date of issue: 09. 2012.

# MANUFACTURER

# PZ CORMAY S.A.

ul. Wiosenna 22, 05-092 Łomianki, POLAND tel.: +48 (0) 81 749 44 00 fax: +48 (0) 81 749 44 34 http://www.pzcormay.pl

09/12/09/12